Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Neutral 66.1%

Neg 0% Neu 66.1% Pos 0%

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.